Cullinan Oncology Inc (CGEM)
11.43
-0.34 (-2.89%)
USD |
NASDAQ |
Feb 06, 14:51
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 449.48M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -8.05% |
| Valuation | |
| PE Ratio | 5.149 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.7669 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
02/03 09:37
Yahoo
02/02 16:01
Yahoo
11/14 07:00
Yahoo
11/02 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/17/2023* | -- | Results | Q4 2022 | -- | -0.71 | -- | |
| 11/14/2022 | -- | Results | Q3 2022 | -- | -0.45 | -- | |
| 08/10/2022 | -- | Results | Q2 2022 | -- | -0.50 | -- | |
| 05/16/2022 | -- | Results | Q1 2022 | -- | -0.47 | -- | |
| 03/17/2022 | -- | Results | Q4 2021 | -0.53 | -0.47 | -10.92% | |
| 11/09/2021 | -- | Results | Q3 2021 | -0.50 | -0.44 | -14.94% | |
| 08/10/2021 | -- | Results | Q2 2021 | -0.36 | -0.42 | 14.29% | |
| 05/14/2021 | -- | Results | Q1 2021 | 0.00 | 0.03 | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. |
| URL | https://www.cullinanoncology.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Mar. 17, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of February 03, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 133.88M |
| Net Income (TTM) | 105.48M |
| Total Assets (Quarterly) | 617.24M |
| Total Liabilities (Quarterly) | 31.11M |
| Shareholders Equity (Quarterly) | 586.13M |
| Cash from Operations (TTM) | -116.85M |
| Cash from Investing (TTM) | 261.72M |
| Cash from Financing (TTM) | 9.681M |
Ratings
Profile
Edit
| Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. |
| URL | https://www.cullinanoncology.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Mar. 17, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CGEM Tweets |